Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nabriva raises $120m to take 'new class of antibiotic' into Phase III

This article was originally published in Scrip

Executive Summary

Nabriva Therapeutics, which is developing a new class antibiotics called pleuromutilins, has raised $120m in a series B financing involving a group of transatlantic investors. CEO Colin Broom told Scrip there was no key piece of data that secured the cash, but rather the "a package combining data from 450 treated patients" including a 200-patient Phase II efficacy trial.

You may also be interested in...

Nabriva Wants To Try A Different Approach To Antibiotic Stewardship

Nabriva sees an opportunity for its Phase III antibiotic lefamulin to be used as a first-line agent against community-acquired bacterial pneumonia, rather than being held in reserve, because it targets pathogens that cause lung infections.

venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments

VenBio has $315m in new cash to invest in a broad array of therapeutics developers now that it has closed its second venture capital fund, which raised $65m more than the VC firm originally intended and reflects big pharma's increasing commitment to backing early-stage life science companies.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts